|7th November 2019
Many stakeholders are confused by precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity? At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video below to get a run down on three core components to consider when commercialising these innovative products.
|3rd April 2020
Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.
|27th March 2020
Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.
|6th March 2020
BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.